Budesonide Prophylaxis for Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation

• Status: Not yet recruiting
• Trial end date: 2025-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Henry Ford Health System
• Treatments: Budesonide

Criteria

Inclusion Criteria:

• • Patients 18-80 years of age with a diagnosis of a hematological malignancy

• Meet the BMT program criteria to undergo hematopoietic stem cell transplantation for hematologi malignancies

Exclusion Criteria:

• • Patients enrolled in investigational clinical trials

• Sct for non hematologic malignancies